Decades of studies provided a detailed view of the mechanism of estrogen receptor-α (ERα) regulated gene transcription and the physio-pathological relevance of the genetic programs controlled by this receptor in a variety of tissues. However, still limited is our knowledge on the regulation of ERα synthesis.

Preliminary observations showed that the expression of ERα is cell cycle regulated. Researchers have demonstrated that a well described polymorphic sequence in the first intron of ERα (PvuII and XbaI) has a key role in regulating the ERα content in cycling cells.
Researchers have shown that the RNA Pol II (Pol II) elongation is blocked at the polymorphic site and that the proto-oncogene c-MYB modulates the release of the pausing polymerase.

It is well known that the two SNPs are associated to an increased risk, progression, survival and mortality of endocrine-related cancers, here researchers have demonstrated that the c-MYB-dependent release of Pol II at a specific phase of the cell cycle is facilitated by the px haplotype, thus leading to a higher ERα mitogenic signal.

In breast cancer, this mechanism is disrupted when the hormone refractory phenotype is established; therefore, researchers propose this oscillator as a novel target for the development of therapies aimed at sensitizing breast cancer resistant to hormonal treatments.

Because PvuII and XbaI were associated to a broad range physio-pathological conditions beside neoplastic transformation, sceintists expect that the ERα oscillator contributes to the regulation of the estrogen signal in several tissues.

For more information
http://m.pnas.org/content/early/2014/06/11/1321750111.abstract

MDN